These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19528309)

  • 21. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired renal function in acute myocardial infarction.
    Lekston A; Kurek A; Tynior B
    Cardiol J; 2009; 16(5):400-6. PubMed ID: 19753517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
    Mori H; Okada Y; Tanaka Y; Hashimoto O
    Clin Calcium; 2012 Jul; 22(7):1034-42. PubMed ID: 22750936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The aggressiveness of urinary tract urothelial carcinoma increases with the severity of chronic kidney disease.
    Hung PH; Shen CH; Chiu YL; Jong IC; Chiang PC; Lin CT; Hung KY; Tsai TJ
    BJU Int; 2009 Nov; 104(10):1471-4. PubMed ID: 19549259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
    Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral bisphosphonate use in the elderly is not associated with acute kidney injury.
    Shih AW; Weir MA; Clemens KK; Yao Z; Gomes T; Mamdani MM; Juurlink DN; Hird A; Hodsman A; Parikh CR; Wald R; Cadarette SM; Garg AX
    Kidney Int; 2012 Oct; 82(8):903-8. PubMed ID: 22695327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.
    Gordon CE; Balk EM; Becker BN; Crooks PA; Jaber BL; Johnson CA; Michael MA; Pereira BJ; Uhlig K; Levin A
    Am J Kidney Dis; 2008 Nov; 52(5):811-25. PubMed ID: 18971009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone disease in elderly individuals with CKD.
    Kansal S; Fried L
    Adv Chronic Kidney Dis; 2010 Jul; 17(4):e41-51. PubMed ID: 20610353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reporting the eGFR and its implication for CKD diagnosis.
    Botev R; Mallié JP
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1606-7. PubMed ID: 18922981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
    Orita H; Yoshimoto W; Tanaka Y; Yamanaka S; Shigematsu T
    Clin Calcium; 2010 May; 20(5):752-7. PubMed ID: 20445287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal function assessment in the era of chronic kidney disease: renewed emphasis on renal function centered patient care.
    Lane BR; Poggio ED; Herts BR; Novick AC; Campbell SC
    J Urol; 2009 Aug; 182(2):435-43; discussion 443-4. PubMed ID: 19524967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrocalcinosis: a potential complication of bisphosphonate therapy in children.
    Jensen DE; McGill J; Batch J
    J Paediatr Child Health; 2011 Dec; 47(12):929-30. PubMed ID: 22171838
    [No Abstract]   [Full Text] [Related]  

  • 37. The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection.
    Onuigbo MA
    Adv Perit Dial; 2009; 25():85-8. PubMed ID: 19886324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding a common language for patient safety in CKD.
    Fink JC; Joy MS; St Peter WL; Wahba IM;
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):689-95. PubMed ID: 22403270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic kidney disease (CKD) and bone. CKD-MBD managements and view in the future].
    Watanabe M; Suzuki H; Akizawa T
    Clin Calcium; 2009 Apr; 19(4):559-65. PubMed ID: 19329836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for CKD in children: a global controversy.
    Hogg RJ
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):509-15. PubMed ID: 19118121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.